OBESITY AS A CHRONIC LOW-GRADE INFLAMMATORY DISEASE - PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL IMPLICATIONS. A REVIEW OF THE LITERATURE
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5981Keywords:
Obesity, Chronic Low-Grade Inflammation, Adipose Tissue, Insulin Resistance, Adipokines, Metabolic Syndrome, Adipocyte HypertrophyAbstract
Obesity is currently recognized as one of the greatest global public health challenges and is increasingly referred to as the pandemic of the 21st century[1,2]. The results of recent analyses confirm that one of the main mechanisms responsible for the development and persistence of obesity and its metabolic and organ-related complications is chronic inflammation in the body[3]. In obesity, one observes immunological remodeling of adipose tissue, increased activation of inflammatory pathways[4], disturbances in adipokine secretion[5], as well as gut dysbiosis and increased intestinal barrier permeability, which exacerbate metabolic endotoxemia and systemic inflammation[6]. These mechanisms contribute to the development of insulin resistance, endothelial dysfunction, and numerous comorbidities, such as type 2 diabetes, cardiovascular diseases, MASLD, neurodegenerative diseases, and cancer[7,8]. Adipose tissue thus functions as an active endocrine-immunological organ that, through the production of inflammatory mediators, influences the metabolic homeostasis of the entire body[9,10]. Recognizing obesity as an inflammatory disease is changing the current treatment paradigm - the goal of therapy is not only weight reduction but also the restoration of immunological and metabolic balance and the mitigation of the long-term consequences of chronic inflammation[11,12]. The development of targeted therapies, modulation of the gut microbiota, and the use of epigenetic mechanisms may represent important avenues for future research and treatment of obesity[13–15]. GLP-1 receptor agonists and multireceptor drugs, which, in addition to their metabolic effects, also exhibit anti-inflammatory properties, are currently showing particularly promising results[7]. The aim of this study is to analyze and summarize the current state of knowledge regarding the role of low-grade chronic inflammation (LGCI) in the pathogenesis of obesity, with particular emphasis on inflammatory mechanisms, the role of adipokines and immune cells, as well as clinical consequences and potential therapeutic strategies.
References
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., Rodriguez-Martinez, A., Bixby, H., Bentham, J., Cesare, M. D., Danaei, G., Rayner, A. W., Barradas-Pires, A., Cowan, M. J., Savin, S., … Ezzati, M. (2024). Worldwide trends in underweight and obesity from 1990 to 2022: A pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. The Lancet, 403(10431), 1027–1050. https://doi.org/10.1016/S0140-6736(23)02750-2
Obesity and overweight. (n.d.). Retrieved May 6, 2026, from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Tanti, J.-F., Ceppo, F., Jager, J., & Berthou, F. (2013). Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Frontiers in Endocrinology, 3. https://doi.org/10.3389/fendo.2012.00181
Khanna, D., Welch, B. S., & Rehman, A. (2026). Pathophysiology of Obesity. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK572076/
Pedro, W. J. S., Barbosa Júnior, F. V., Alves, F. N. B. R., Braga, L. V., Alves, L. R., Afonso, J. P. R., Silva, I. O., Silva, C. H. M., Vencio, S., Capodaglio, P., Oliveira, L. V. F., & Freitas Júnior, W. R. (2025). Role of Adipokines Chemerin, Visfatin, and Omentin in Obesity and Their Inflammatory and Metabolic Implications. Biomedicines, 13(10), 2321. https://doi.org/10.3390/biomedicines13102321
Spanorriga, M.-K., Fragoulis, C., Bega, I., Mavromoustakou, K., Gatsouniotis, I., Lontou, S.-P., Dimitriadis, K., Aznaouridis, K., Ktenopoulos, N., Thanopoulou, A., Chrysohoou, C., & Tsioufis, K. (2026). Innovative regenerative genetic and nano therapies for diabetes and metabolic disease. Exploration of Endocrine and Metabolic Diseases, 3, 101461. https://doi.org/10.37349/eemd.2026.101461
Gkrinia, E. M. M., & Belančić, A. (2025). The Mechanisms of Chronic Inflammation in Obesity and Potential Therapeutic Strategies: A Narrative Review. Current Issues in Molecular Biology, 47(5), 357. https://doi.org/10.3390/cimb47050357
Yang, X., Wang, X., Tang, H., Tu, S., Yin, K., & Zhu, X. (2026). m6A in adipose tissue inflammation: A novel regulator of obesity and metabolic diseases (Review). International Journal of Molecular Medicine, 57(5), 1–17. https://doi.org/10.3892/ijmm.2026.5795
Wojciechowski, K., Balcerek, A., Kobusińska, K., Służewska, J., Trojan, M., Krawczyński, M., Śmigielski, M., & Pelczyńska, M. (2022). Udział tkanki tłuszczowej w powstawaniu zaburzeń metabolicznych. Forum Leczenia Otyłości, 13(3), 75–84.
Ramírez-Moreno, E., Arias-Rico, J., Jiménez-Sánchez, R. C., Estrada-Luna, D., Jiménez-Osorio, A. S., Zafra-Rojas, Q. Y., Ariza-Ortega, J. A., Flores-Chávez, O. R., Morales-Castillejos, L., & Sandoval-Gallegos, E. M. (2022). Role of Bioactive Compounds in Obesity: Metabolic Mechanism Focused on Inflammation. Foods, 11(9), 1232. https://doi.org/10.3390/foods11091232
Sobreviela Sánchez, S., Giusfredi Quevedo, R., Fernandes, T., & da Fonseca, G. W. P. (2025). The role of exercise and nutrition in modulating inflammatory cytokines activity for obesity management. Frontiers in Endocrinology, 16. https://doi.org/10.3389/fendo.2025.1618360
Ballesteros-Pomar, M. D., & Barazzoni, R. (2026). Why obesity is a disease—Pathogenesis and diagnosis. Clinical Nutrition ESPEN, 72. https://doi.org/10.1016/j.clnesp.2026.102922
Chamarthi, V. S., & Daley, S. F. (2025). Obesity as a Chronic Disease: Epidemiology and Pathophysiologic Insights. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/sites/books/NBK618380/
Khademi, Z., Mahmoudi, Z., Sukhorukov, V. N., Jamialahmadi, T., & Sahebkar, A. (n.d.). CRISPR/Cas9 Technology: A Novel Approach to Obesity Research. Current Pharmaceutical Design, 30(23), 1791–1803. https://doi.org/10.2174/0113816128301465240517065848
Bock, P. M., Martins, A. F., & Schaan, B. D. (2024). Understanding how pre- and probiotics affect the gut microbiome and metabolic health. American Journal of Physiology-Endocrinology and Metabolism, 327(1), E89–E102. https://doi.org/10.1152/ajpendo.00054.2024
Levels and trends in child malnutrition: UNICEF/WHO/World Bank Group joint child malnutrition estimates: key findings of the 2025 edition. (n.d.). Retrieved May 6, 2026, from https://www.who.int/publications/i/item/9789240112308
Brauer, M., Roth, G. A., Aravkin, A. Y., Zheng, P., Abate, K. H., Abate, Y. H., Abbafati, C., Abbasgholizadeh, R., Abbasi, M. A., Abbasian, M., Abbasifard, M., Abbasi-Kangevari, M., ElHafeez, S. A., Abd-Elsalam, S., Abdi, P., Abdollahi, M., Abdoun, M., Abdulah, D. M., Abdullahi, A., … Gakidou, E. (2024). Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet, 403(10440), 2162–2203. https://doi.org/10.1016/S0140-6736(24)00933-4
Saadati, S., Godini, R., Reddy, A., Teede, H., & Mousa, A. (2025). Metabolic crossroads in insulin resistance: Exploring lipid dysregulation and inflammation. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1692742
Banerjee, D., & Mani, A. (2025). Obesity’s systemic impact: Exploring molecular and physiological links to diabetes, cardiovascular disease, and heart failure. Frontiers in Endocrinology, 16. https://doi.org/10.3389/fendo.2025.1681766
Michailidou, Z., Gomez-Salazar, M., & Alexaki, V. I. (2022). Innate Immune Cells in the Adipose Tissue in Health and Metabolic Disease. Journal of Innate Immunity, 14(1), 4–30. https://doi.org/10.1159/000515117
Matulewicz, N., & Karczewska-Kupczewska, M. (2016). Insulin resistance and chronic inflammation. Postepy Higieny I Medycyny Doswiadczalnej, 70(0), 1245–1258.
Varra, F.-N., Varras, M., Varra, V.-K., & Theodosis-Nobelos, P. (2024). Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review). Molecular Medicine Reports, 29(6), 1–27. https://doi.org/10.3892/mmr.2024.13219
Pacholczyk, M., Ferenc, T., & Kowalski, J. (n.d.). Zespół metaboliczny. Część II: patogeneza zespołu metabolicznego i jego powikłań. Postepy Hig Med Dosw.
Choi, W., Woo, G. H., Kwon, T.-H., & Jeon, J.-H. (2025). Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction. International Journal of Molecular Sciences, 26(19), 9715. https://doi.org/10.3390/ijms26199715
ESE Clinical Update on Obesity 2021. (n.d.). Retrieved May 6, 2026, from https://www.ese-hormones.org/publications/directory/ese-clinical-update-on-obesity-2021/
Kochar Kaur, K., Allahbadia, G., & Singh, M. (2022). An Update of Use of Therapeutic Targeting of Macrophages Polarization Status in the Treatment of Obesity Induced Insulin Resistance, Chronic Inflammation and Type2 Diabetes Mellitus—A Narrative Review. 7, 1–18.
Marcelin, G., Gautier, E. L., & Clément, K. (2022). Adipose Tissue Fibrosis in Obesity: Etiology and Challenges. Annual Review of Physiology, 84(Volume 84, 2022), 135–155. https://doi.org/10.1146/annurev-physiol-060721-092930
Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007). Obesity induces a phenotypic switch in adipose tissue macrophage polarization. The Journal of Clinical Investigation, 117(1), 175–184. https://doi.org/10.1172/JCI29881
Sung, J., Ho, C.-T., & Wang, Y. (2018). Preventive mechanism of bioactive dietary foods on obesity-related inflammation and diseases. Food & Function, 9(12), 6081–6095. https://doi.org/10.1039/c8fo01561a
Yang, H.-Y., Wei, Y., Mao, Q., & Zhao, L.-H. (2025). Immune activation induced by dysregulated lipid metabolism in the pathogenesis of type 2 diabetes. World Journal of Diabetes, 16(12). https://doi.org/10.4239/wjd.v16.i12.114395
Olszówka, M., & Zdunek, B. (Eds.). (2016). Najnowsze badania z zakresu chorób nowotworowych. Wydawnictwo Naukowe Tygiel.
Gao, F., Litchfield, B., & Wu, H. (2024). Adipose tissue lymphocytes and obesity. The Journal of Cardiovascular Aging, 4(1), N/A-N/A. https://doi.org/10.20517/jca.2023.38
Gutiérrez-Rodelo, C., Roura-Guiberna, A., & Olivares-Reyes, J. A. (2017). [Molecular Mechanisms of Insulin Resistance: An Update]. Gaceta Medica De Mexico, 153(2), 214–228.
Czerkies, M., & Kwiatkowska, K. (2014). Toll-Like Receptors and their Contribution to Innate Immunity: Focus on TLR4 Activation by Lipopolysaccharide. Advances in Cell Biology, 4(1), 1–23. https://doi.org/10.2478/acb-2014-0001
Łacheta, D., Olejarz, W., Wrzosek, M., & Nowicka, G. (2023, June 12). Receptory Toll-podobne jako potencjalny cel terapeutyczny w miażdżycy i chorobach sercowo-naczyniowych. PHMD. https://phmd.hirszfeld.pl/receptory-toll-podobne-jako-potencjalny-cel-terapeutyczny-w-miazdzycy-i-chorobach-sercowo-naczyniowych/
Wang, F., & Mo, Z. (2020). NLRP3 inflammasome in metabolic syndrome. Brazilian Journal of Pharmaceutical Sciences, 56, e18968. https://doi.org/10.1590/s2175-97902020000118968
Swanson, K. V., Deng, M., & Ting, J. P.-Y. (n.d.). The NLRP3 inflammasome: Molecular activation and regulation to therapeutics | Nature Reviews Immunology. Retrieved May 14, 2026, from https://www.nature.com/articles/s41577-019-0165-0
Krzyżowska, M., Świątek, W., Fijałkowska, B., Niemiałtowski, M., & Schollenberger, A. (n.d.). Rola kinaz MAP w odpowiedzi immunologicznej | Kwartalnik PBK. Retrieved May 14, 2026, from https://www.pbkom.eu/pl/content/rola-kinaz-map-w-odpowiedzi-immunologicznej
Juszczyk, K. (2022). Profil ekspresji genów kinaz aktywowanych mitogenami (MAP) w monitorowaniu terapii adalimumabem u chorych na łuszczycę stawową [Thesis, Zakład Biologii Molekularnej]. https://ppm.sum.edu.pl/info/phd/SUMdc8589d394eb4a59a395733bf2ec165a/?ps=20&lang=pl&pn=1&cid=20500
Liu, J., Minemoto, Y., & Lin, A. (2004). C-Jun N-Terminal Protein Kinase 1 (JNK1), but Not JNK2, Is Essential for Tumor Necrosis Factor Alpha-Induced c-Jun Kinase Activation and Apoptosis. Molecular and Cellular Biology, 24(24), 10844–10856. https://doi.org/10.1128/MCB.24.24.10844-10856.2004
Bremer, A. A., & Miller, W. L. (2008). The serine phosphorylation hypothesis of polycystic ovary syndrome: A unifying mechanism for hyperandrogenemia and insulin resistance. Fertility and Sterility, 89(5), 1039–1048. https://doi.org/10.1016/j.fertnstert.2008.02.091
Xu, S., Xi, J., Wu, T., & Wang, Z. (2023). The Role of Adipocyte Endoplasmic Reticulum Stress in Obese Adipose Tissue Dysfunction: A Review. International Journal of General Medicine, 16, 4405–4418. https://doi.org/10.2147/IJGM.S428482
Read, A., & Schröder, M. (2021). The Unfolded Protein Response: An Overview. Biology, 10(5), 384. https://doi.org/10.3390/biology10050384
Clemente-Suárez, V. J., Redondo-Flórez, L., Beltrán-Velasco, A. I., Martín-Rodríguez, A., Martínez-Guardado, I., Navarro-Jiménez, E., Laborde-Cárdenas, C. C., & Tornero-Aguilera, J. F. (2023). The Role of Adipokines in Health and Disease. Biomedicines, 11(5), 1290. https://doi.org/10.3390/biomedicines11051290
Olszanecka-Glinianowicz, M., Kocełak, P., Orlik, B., Handzlik, G., & Juszczyk, Ł. (2009). Nowe adipokiny—Korzystne czy niekorzystne w aspekcie patogenezy insulinooporności? Endokrynologia, Otyłość i Zaburzenia Przemiany Materii, 5(4), 236–244.
Wunderlich, C. M., Hövelmeyer, N., & Wunderlich, F. T. (2013). Mechanisms of chronic JAK-STAT3-SOCS3 signaling in obesity. JAK-STAT, 2(2). https://doi.org/10.4161/jkst.23878
Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020). The intestinal microbiota fuelling metabolic inflammation. Nature Reviews Immunology, 20(1), 40–54. https://doi.org/10.1038/s41577-019-0198-4
Pérez-Pérez, A., Sánchez-Jiménez, F., Vilariño-García, T., & Sánchez-Margalet, V. (2020). Role of Leptin in Inflammation and Vice Versa. International Journal of Molecular Sciences, 21(16), 5887. https://doi.org/10.3390/ijms21165887
Solleiro-Villavicencio, H., Viurcos-Sanabria, R., Aguayo-Guerrero, J. A., Pineda-Pérez, P. F., & Méndez-García, L. A. (2025). Inflammation: A key mechanism connecting metabolic-associated steatotic liver disease and systemic arterial hypertension. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1620585
Dobrowolski, P., Prejbisz, A., Jankowski, P., Gil, R. J., Grabowski, M., Gziut-Rudkowska, A. I., Narkiewicz, K., Lelonek, M., & Rozentryt, P. (2024). Postępowanie w chorobach sercowo-naczyniowych u pacjentów z otyłością—Stanowisko ekspertów. Polish Heart Journal (Kardiologia Polska), 82(I), 93–107.
Taylor, R., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Sattar, N., Welsh, P., Peters, C., Zhyzhneuskaya, S., Hollingsworth, K. G., AlMrabeh, A., Rodrigues, A. M., Rehackova, L., Adamson, A. J., Sniehotta, F. F., Mathers, J. C., Ross, H. M., McIlvenna, Y., … Lean, M. E. J. (2018). Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohort. Diabetologia. https://doi.org/10.1007/s00125-017-4503-0
Xin, Y., Davies, A., Briggs, A., McCombie, L., Messow, C. M., Grieve, E., Leslie, W. S., Taylor, R., & Lean, M. E. J. (2020). Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme. Diabetologia, 63(10), 2112–2122. https://doi.org/10.1007/s00125-020-05224-2
McInnes, N., Smith, A., Otto, R., Vandermey, J., Punthakee, Z., Sherifali, D., Balasubramanian, K., Hall, S., & Gerstein, H. C. (2017). Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial. The Journal of Clinical Endocrinology and Metabolism, 102(5), 1596–1605. https://doi.org/10.1210/jc.2016-3373
Duan, Y., Pan, X., Luo, J., Xiao, X., Li, J., Bestman, P. L., & Luo, M. (2022). Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.880298
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016). The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism: Clinical and Experimental, 65(8), 1038–1048. https://doi.org/10.1016/j.metabol.2015.12.012
Luo, Y., & Lin, H. (2021). Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. Immunity, Inflammation and Disease, 9(1), 59–73. https://doi.org/10.1002/iid3.391
Ullah, A., Hu, S., & Shen, B. (2026). Precision nutrition for NAFLD: A mechanistic rationale for targeting the cytokine landscape. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1745316
Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. Nature, 444(7121), 860–867. https://doi.org/10.1038/nature05485
Jayaraj, R. L., & Aburawi, E. H. (2025). Mechanistic relationship between obesity-induced inflammation triggering endothelial dysfunction and the initiation of atherosclerosis development. Heart, Vessels and Transplantation, 9(Issue 1). https://doi.org/10.24969/hvt.2024.542
Sun, B., & Karin, M. (2012). Obesity, inflammation, and liver cancer. Journal of Hepatology, 56(3), 704–713. https://doi.org/10.1016/j.jhep.2011.09.020
Kern, L., Mittenbühler, M. J., Vesting, A. J., Ostermann, A. L., Wunderlich, C. M., & Wunderlich, F. T. (2019). Obesity-Induced TNFα and IL-6 Signaling: The Missing Link between Obesity and Inflammation—Driven Liver and Colorectal Cancers. Cancers, 11(1), 24. https://doi.org/10.3390/cancers11010024
Koskinas, K. C., Van Craenenbroeck, E. M., Antoniades, C., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., Prescott, E. B., & the ESC Scientific Document Group. (2024). Obesity and cardiovascular disease: An ESC clinical consensus statement. European Heart Journal, 45(38), 4063–4098. https://doi.org/10.1093/eurheartj/ehae508
Rajput, M., Malik, I. A., Methi, A., Cortés Silva, J. A., Fey, D., Wirths, O., Fischer, A., Wilting, J., & von Arnim, C. A. F. (2025). Cognitive decline and neuroinflammation in a mouse model of obesity: An accelerating role of ageing. Brain, Behavior, and Immunity, 125, 226–239. https://doi.org/10.1016/j.bbi.2024.12.154
Vlăsceanu, V. I., Timofeiov, S., Pînzariu, A. C., Soroceanu, R. P., Maxim, M., Ambrosie, L., Miler, A. A., Cojocaru, T., Cojocaru, G. M., Leonte, S. M., Trofin, A. G., & Timofte, D. V. (2026). Linking Obesity and Depression Through the Gut–Brain Axis: The Impact of Short-Chain Fatty Acids and Inflammation. Nutrients, 18(6), 898. https://doi.org/10.3390/nu18060898
Pirozzi, C., Opallo, N., Del Piano, F., Melini, S., & Lama, A. (2025). Body and mind: How obesity triggers neuropsychiatric and neurodegenerative disorders. Frontiers in Psychiatry, 15. https://doi.org/10.3389/fpsyt.2024.1524555
Liu, K., Liu, S., Wang, D., & Qiao, H. (2026). Obesity-induced cognitive impairment: Underlying mechanisms and therapeutic prospects. Metabolism Open, 29, 100444. https://doi.org/10.1016/j.metop.2026.100444
Vuković, M., Nosek, I., Medić Stojanoska, M., & Kozić, D. (2026). Neurometabolic and Neuroinflammatory Consequences of Obesity: Insights into Brain Vulnerability and Imaging-Based Biomarkers. International Journal of Molecular Sciences, 27(2), 958. https://doi.org/10.3390/ijms27020958
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024). Pathogenesis, diagnostics, and therapeutics for Alzheimer’s disease: Breaking the memory barrier. Ageing Research Reviews, 101, 102481. https://doi.org/10.1016/j.arr.2024.102481
Spielman, L. J., Little, J. P., & Klegeris, A. (2014). Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. Journal of Neuroimmunology, 273(1), 8–21. https://doi.org/10.1016/j.jneuroim.2014.06.004
Romero, D. G., Basnet, J., & Yanes Cardozo, L. L. (2025). Back to the Drawing Board: Rethinking Inflammation in Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, dgaf685. https://doi.org/10.1210/clinem/dgaf685
Baranowska-Bik, A. (2022). Therapy of obesity in women with PCOS using GLP-1 analogues—Benefits and limitations [Terapia otyłości u kobiet z PCOS przy zastosowaniu analogów GLP-1—Korzyści i ograniczenia]. Endokrynologia Polska, 73(3), 627–643. https://doi.org/10.5603/EP.a2022.0047
Rabijewski, M. (2023). Male-specific consequences of obesity—Functional hypogonadism and fertility disorders. Endokrynologia Polska, 74(5), 480–489. https://doi.org/10.5603/ep.95626
Armeni, E. (2023). Male hypogonadism in overweight and obesity. Metabolism and Target Organ Damage, 3(2), N/A-N/A. https://doi.org/10.20517/mtod.2023.05
Santi, D., Lotti, F., Sparano, C., Rastrelli, G., Isidori, A. M., Pivonello, R., Barbonetti, A., Salonia, A., Minhas, S., Krausz, C., Vignozzi, L., Maggi, M., & Corona, G. (2024). Does an increase in adipose tissue ‘weight’ affect male fertility? A systematic review and meta-analysis based on semen analysis performed using the WHO 2010 criteria. Andrology, 12(1), 123–136. https://doi.org/10.1111/andr.13460
Rivera-Carranza, T., León-Téllez-Girón, A., González-Vázquez, R., Vázquez-Cárdenas, P., Esquivel-Campos, A. L., Mendoza-Pérez, F., Rojano-Rodríguez, M. E., Mimiaga-Hernández, C., Cifuentes-Goches, J. C., Peralta-Valle, O. E., Zúñiga-León, E., & Bojalil-Parra, R. (2025). Cellular Immunity in Obesity: Pathophysiological Insights and the Impact of Bariatric Surgery. International Journal of Molecular Sciences, 26(20), 9867. https://doi.org/10.3390/ijms26209867
Saito, R., Hirakawa, J., Kuwamura, M., & Hoshina, T. (2025). Alterations in peripheral CD4+ T cell subsets and their association with metabolic markers in obese children. Frontiers in Endocrinology, 16. https://doi.org/10.3389/fendo.2025.1635379
Green, W. D., Al-Shaer, A. E., Shi, Q., Gowdy, K. M., MacIver, N. J., Milner, J. J., Beck, M. A., & Shaikh, S. R. (2022). Metabolic and functional impairment of CD8+ T cells from the lungs of influenza-infected obese mice. Journal of Leukocyte Biology, 111(1), 147–159. https://doi.org/10.1002/JLB.4A0120-075RR
Ros-Madrid, I., Cano-Mármol, R. P., Ferrer-Gomez, M., & Ramos-Molina, B. (2025). Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective. Canadian Journal of Physiology and Pharmacology, 103(12), 369–377. https://doi.org/10.1139/cjpp-2025-0148
AL-shibil, Z. M. R., & Kadhim, Z. J. (2026). Effect of retatrutide on body weight, lipid profile, liver function, oxidative stress, and inflammation in experimental obesity in male rats. European Journal of Clinical and Experimental Medicine, 24(1), 150–163. https://doi.org/10.15584/ejcem.2026.1.26
Shivappa, N., Steck, S. E., Hurley, T. G., Hussey, J. R., & Hébert, J. R. (2014). Designing and developing a literature-derived, population-based dietary inflammatory index. Public Health Nutrition, 17(8), 1689–1696. https://doi.org/10.1017/S1368980013002115
Florkowski, M., Abiona, E., Frank, K. M., & Brichacek, A. L. (2024). Obesity-associated inflammation countered by a Mediterranean diet: The role of gut-derived metabolites. Frontiers in Nutrition, 11. https://doi.org/10.3389/fnut.2024.1392666
Kezer, G., Paramithiotis, S., Khwaldia, K., Harahap, I. A., Čagalj, M., Šimat, V., Smaoui, S., Elfalleh, W., Ozogul, F., & Esatbeyoglu, T. (2025). A comprehensive overview of the effects of probiotics, prebiotics and synbiotics on the gut-brain axis. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1651965
Kopp, L., Schweinlin, A., Tingö, L., Hutchinson, A. N., Feit, V., Jähnichen, T., Lehnert, K., Vetter, W., Rings, A., Jensen, M. G., Brummer, R. J., & Bischoff, S. C. (2023). Potential Modulation of Inflammation and Physical Function by Combined Probiotics, Omega-3 Supplementation and Vitamin D Supplementation in Overweight/Obese Patients with Chronic Low-Grade Inflammation: A Randomized, Placebo-Controlled Trial. International Journal of Molecular Sciences, 24(10), 8567. https://doi.org/10.3390/ijms24108567
He, X., Chen, C., Shen, L., Su, X., Xie, H., Yang, M., & Jiang, W. (2026). Retrospective insights into probiotic and prebiotic interventions: Associations with gut microbiota profiles and nutritional outcomes. Frontiers in Nutrition, 13. https://doi.org/10.3389/fnut.2026.1729480
Setayesh, A., Karimi, M., Valizadeh, F., Asbaghi, O., Pirzad, S., Davoodi, S. H., & Larijani, B. (2025). Probiotics and Synbiotics Supplementation Reduce Inflammatory Cytokines in Individuals with Prediabetes and Type 2 Diabetes Mellitus: Findings from a Systematic Review Meta-analysis. Advances in Nutrition, 16(11), 100526. https://doi.org/10.1016/j.advnut.2025.100526
Cao, P., Yang, Y., Zhang, N., Wang, B., & Gong, Z. (2025). Inflammasomes: Novel therapeutic targets for metabolic syndrome? Frontiers in Endocrinology, 16. https://doi.org/10.3389/fendo.2025.1569579
Liu, D., Zhou, C., Wang, X., Luo, Z., Xu, R., Huo, S., Guo, L., Luo, X., Yang, S., Click, A., Vancil, J., Barajas, P., Mijares, V., Baniasadi, H., Yan, N., Rehwinkel, J., Hancks, D. C., Chen, E. H., Liang, S., & Zhong, Z. (2026). Nucleotide metabolic rewiring enables NLRP3 inflammasome hyperactivation in obesity. Science, 391(6782), eadq9006. https://doi.org/10.1126/science.adq9006
Jesus, J. de C. R. de, Murari, A. S. de P., Radloff, K., Moraes, R. C. M. de, Figuerêdo, R. G., Pessoa, A. F. M., Rosa-Neto, J. C., Matos-Neto, E. M., Alcântara, P. S. M., Tokeshi, F., Maximiano, L. F., Bin, F. C., Formiga, F. B., Otoch, J. P., & Seelaender, M. (2021). Activation of the Adipose Tissue NLRP3 Inflammasome Pathway in Cancer Cachexia. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.729182
Mohaghegh, N., Ahari, A., Buttles, C., Davani, S., Hoang, H., Huang, Q., Huang, Y., Hosseinpour, B., Abbasgholizadeh, R., Cottingham, A. L., Farhadi, N., Akbari, M., Kang, H., Khademhosseini, A., Jucaud, V., Pearson, R. M., & Hassani Najafabadi, A. (2024). Simvastatin-Loaded Polymeric Nanoparticles: Targeting Inflammatory Macrophages for Local Adipose Tissue Browning in Obesity Treatment. ACS Nano, 18(40), 27764–27781. https://doi.org/10.1021/acsnano.4c10742
Blüher, M. (2012). Clinical Relevance of Adipokines. Diabetes & Metabolism Journal, 36(5), 317–327. https://doi.org/10.4093/dmj.2012.36.5.317
Würfel, M., Blüher, M., Stumvoll, M., Ebert, T., Kovacs, P., Tönjes, A., & Breitfeld, J. (2023). Adipokines as Clinically Relevant Therapeutic Targets in Obesity. Biomedicines, 11(5), 1427. https://doi.org/10.3390/biomedicines11051427
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Iga Kuba, Mikołaj Góralczyk, Jakub Idziński, Anna Lubomska, Julita Jagodzińska, Martyna Grześkowiak, Maria Bieske, Jakub Sapikowski, Agata Juchniewicz, Igor Jętasiewicz
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
